BIG PHARMA WATCH: MERCK PLOTS TO FURTHER BLOCK COMPETITION AND EXTEND MONOPOLY PRICING ON BLOCKBUSTER CANCER DRUG KEYTRUDA

12-2-2022 Blog Posts

Big Pharma Giant Wants New Patents for Formulation Changes That Won’t Improve Clinical Benefit of Cancer Drug — Adding to Existing Patent Thicket of 129 Filed Applications On Friday, Big Pharma giant Merck announced that it will seek new patents on its blockbuster cancer drug Keytruda, which last year brought in over $17 billion for […]

BIG PHARMA WATCH: DRUG COMPANY VERTEX PRICE-GOUGING BRAND NAME CYSTIC FIBROSIS TREATMENTS AND BANKING HUGE PROFITS

11-30-2022 Blog Posts

Patient Advocates Warn Access to Egregiously Priced Treatments at Risk Drug company Vertex manufacturers four key cystic fibrosis (CF) treatments, Trikafta, Symdeko, Orkambi, and Kalydeco that all carry price tags far exceeding estimates for a fair price — threatening access to these lifesaving medicines for patients. Vertex set list prices on three of the treatments […]

TWO BIRDS OF A FEATHER: BIG PHARMA COMPANIES EYE MERGER TO UNDERMINE GENERIC COMPETITION TO OPIOID TREATMENTS

11-16-2022 Blog Posts

Brand Name Drug Company to Acquire Manufacturer of Narcan as Both Work to Block Competition from More Affordable Alternatives In case you missed it, on Monday pharmaceutical company Indivior announced plans to acquire Opiant Pharmaceuticals as part of an effort to consolidate market power over opioid addiction and opioid treatments and undermine access to more […]

BIG PHARMA EARNINGS WATCH: GLAXOSMITHKLINE, AMGEN, ASTRAZENECA

11-11-2022 Blog Posts

Big Pharma Giants Notch Expectation-Busting Earnings After Continuing to Hike Drug Prices A final round of Big Pharma third quarter earnings reports from GlaxoSmithKline, Amgen and AstraZeneca showed the pharmaceutical industry continues to ride high on bigtime profits fueled by continued bigtime price-gouging. Driven by increasing revenue from pharmaceutical divisions and strong COVID-19 vaccine and […]

BIG PHARMA EARNINGS WATCH: PFIZER, ABBVIE, SANOFI, ELI LILLY

11-4-2022 Blog Posts

Big Pharma Giants Beat Wall Street Expectations After Year of Price Increases, Pfizer’s Bourla Pressed on “Sheer Magnitude” of COVID-19 Vaccine Price Hike on Earnings Call Big Pharma companies Pfizer, AbbVie, Sanofi, and Eli Lilly all topped Wall Street expectations in third quarter earnings reports this week — as all four companies continue to engage […]

BIG PHARMA WATCH: REPRESENTATIVE KATIE PORTER HIGHLIGHTS BIG PHARMA’S OUTRAGEOUS CANCER DRUG LAUNCH PRICES

11-3-2022 Blog Posts

New Report Finds Brand Name Drug Companies Increased Prices on New Oncology Treatments by 25 Percent Over Four Years This week, U.S. Representative Katie Porter (D-CA) released a report, “Skyrocketing: How Big Pharma Exploits Launch Prices to Cash in on Cancer,” investigating Big Pharma’s increasingly outrageous launch prices on new cancer drugs — and adding for […]

DOSE OF REALITY: NEW STUDY UNDERSCORES BIG PHARMA’S PRICING PRACTICES ARE ABOUT PROFITS, NOT VALUE FOR PATIENTS

11-1-2022 Blog Posts

JAMA Analysis Finds No Correlation Between Cancer Drug Prices and Effectiveness A new study published in the Journal of the American Medical Association (JAMA) Internal Medicine found a lack of correlation between the prices set by Big Pharma on cancer drugs and their effectiveness for patients. “We did not detect a meaningful association between cancer drug prices […]

BIG PHARMA EARNINGS WATCH: MERCK, BRISTOL MYERS SQUIBB, NOVARTIS

10-28-2022 Blog Posts

New Earnings Reports Show Big Pharma Giants Basking in Massive Profits, Beating Wall Street Expectations After Repeatedly Hiking Drug Prices New earnings reports for the third quarter of 2022 continue to demonstrate the pharmaceutical industry is basking in massive profits after repeated price hikes on brand name prescription drugs in their portfolios. Big Pharma giants […]

BIG PHARMA WATCH: DRUG MAKER PRICES CHEMO TREATMENT TEN TIMES ABOVE THE MARKET AS PATIENTS FACE SHORTAGES

10-28-2022 Blog Posts

Areva Pharmaceuticals Price-Gouges Cancer Patients Who Rely on Older Oncology Drug This week, Areva Pharmaceuticals, a U.S.-based drugmaker, brought an older oncology treatment to market used for patients suffering from certain forms of Leukemia. According to reports, the drug, fludarabine, has been in short supply and hospitals and cancer centers have struggled to secure supplies […]

BIG PHARMA WATCH: BIG PHARMA’S EGREGIOUS PRICING PRACTICES FORCE MORE THAN ONE MILLION AMERICANS TO RATION INSULIN DUE TO COST

10-20-2022 Blog Posts

The Problem with Insulin Affordability is the Price, Driven by “Shadow Pricing” Tactics from Brand Name Drug Companies In case you missed it, a new study published in the Annals of Internal Medicine estimated that more than 1.3 million Americans, more than 16 percent of adults prescribed insulin, did not take the drug as prescribed […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.